Supplementary information

On resin synthesis of phosphoethanolamine cellulose

Jhih-Yi Huang^{a,b} and Martina Delbianco^{*a}

a. Department of Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1, 14476 Potsdam, Germany.

b. Department of Chemistry and Biochemistry, Freie Universitäte Berlin, Arnimallee 22, 14195 Berlin, Germany.

Table of Contents

1. Chemical synthesis

All chemicals used were reagent grade and used as supplied unless otherwise noted. The automated syntheses were performed on a home-built synthesizer developed at the Max Planck Institute of Colloids and Interfaces¹, or the commercial synthesizer Glyconeer 3.1 (GlycoUniverse, Germany). Analytical thin-layer chromatography (TLC) was performed on Merck silica gel 60 F254 plates (0.25 mm). Compounds were visualized by UV irradiation or dipping the plate in a staining solution (sugar stain: 10% H₂SO₄ in EtOH; CAM: 48 g/L ammonium molybdate, 60 g/L ceric ammonium molybdate in 6% H2SO⁴ aqueous solution). Flash column chromatography was carried out by using forced flow of the indicated solvent on Fluka Kieselgel 60 M (0.04 – 0.063 mm). Analysis and purification by reverse phase HPLC was performed by using an Agilent 1260 series equipped with an evaporative light scattering detector (ELSD). Products were lyophilized using a Christ Alpha 2-4 LD plus freeze dryer. 1H, 13C, ³¹P and HSQC NMR spectra were recorded on a Bruker 400-MR (400 MHz), Varian 600-MR (600 MHz), or Bruker Biospin AVANCE700 (700 MHz) spectrometer. Spectra were recorded in CDCl₃ or D_2O using the solvent as the internal standard in ¹H NMR (CDCl₃,: 7.26 ppm ¹H, D₂O: 4.79 ppm ¹H). The 1H NMR were acquired without heteroatom decoupling. The 13C and 31P were acquired with hydrogen atom decoupling. 1H NMR integrals of the resonances corresponding to residues at the reducing end are reported as non-integer numbers and the sum of the integrals of α and β anomers is set to 1. NMR spectra were processed using MestreNova 14.3 (MestreLab Research). High resolution mass spectra were obtained using a 6210 ESI-TOF mass spectrometer (Agilent) and a MALDI-TOF autoflexTM (Bruker). MALDI and ESI mass spectra were run on IonSpec Ultima instruments.

2. Building blocks for AGA

Figure S1 BBs and solid supports used in this work.

Building block **BB1a** and **BB3** were purchased from GlycoUniverse (Germany). Building block **BB1b**, **BB2a** and **BB2b** were synthesized according to previously reported procedures.^{2, 3} Merrifield resin equipped with a photocleavable linker (**L1**, loading 0.35 mmol/g and **L2**, loading 0.40 mmol/g) was prepared according to previous literature.4

3. Automated glycan assembly

3.1 General materials and methods

The automated syntheses were performed on a home-built synthesizer developed at the Max Planck Institute of Colloids and Interfaces or the commercial synthesizer Glyconeer 3.1 (GlycoUniverse, Germany). All solvents used were HPLC-grade. The solvents used for the building blocks, activator, TMSOTf and capping solutions were taken from an anhydrous solvent system (J.C. Meyer). The building blocks were co-evaporated three times with toluene and dried for 1 h on high vacuum before use. Oven-heated, argon-flushed flasks were used to prepare all moisture-sensitive solutions. Activator, capping, deprotection, acidic wash and building block solutions were freshly prepared and kept under argon during the automation run. All yields of products obtained by AGA were calculated on the basis of resin loading. Resin loading was determined following previously established procedures.⁵

3.2 Preparation of stock solutions

- **Building block solution**: Between 0.05 and 0.10 mmol of building block (depending on the BB, see Module C1 and C2) was dissolved in $CH₂Cl₂$ (1 mL).
- **NIS/TfOH activator solution**: 1.35 g (6.0 mmol) of recrystallized NIS was dissolved in 40 mL of a 2:1 v/v mixture of anhydrous CH₂Cl₂ and anhydrous dioxane. Then triflic acid (55 μ L, 0.6 mmol) was added. The solution was kept at $0^{\circ}C$ (ice bath) for the duration of the automation run.
- **Fmoc deprotection solution**: A solution of 20% v/v piperidine in DMF was prepared.
- **Lev deprotection solution**: Hydrazine acetate (550 mg, 5.97 mmol) was dissolved in pyridine/AcOH/H₂O (40 mL, v/v , 32:8:2) and sonicated for 10 min.
- **TMSOTf solution**: TMSOTf $(0.45 \text{ mL}, 2.49 \text{ mmol})$ was added to CH_2Cl_2 (40 mL).
- **TMSOTf solution 2**: TMSOTf $(0.2 \text{ mL}, 1.1 \text{ mmol})$ was added to CH_2Cl_2 (80 mL) . This solution was used for the synthesis of **APA⁴** and **(AP)³** with **BB1b** and **BB2b**.
- **Capping solution**: A solution of $10\%_{\text{v/v}}$ acetic anhydride and $2\%_{\text{v/v}}$ methanesulfunic acid in CH₂Cl₂ was prepared.

3.3 Modules for automated synthesis

Module A: Resin preparation

All automated syntheses were performed on 0.0125 mmol scale. Resin (**L1** or **L2**) is placed in the reaction vessel and swollen in CH2Cl² for 20 min at room temperature prior to the synthesis. During this time, all reagent lines needed for the synthesis are washed and primed. After the swelling, the resin is washed with DMF, THF, and $CH₂Cl₂$ (three times each with 2 mL for 25 s).

Module B: Acidic wash with TMSOTf solution (20 min)

The resin is swollen in 2 mL CH₂Cl₂ and the temperature of the reaction vessel adjusted to -20 $^{\circ}$ C. Upon reaching the low temperature, TMSOTf solution (1 mL) is added dropwise to the reaction vessel. After bubbling for 3 min, the acidic solution is drained and the resin is washed with $2 \text{ mL } CH_2Cl_2$ for 25 s .

*Time required to reach the desired temperature.

Module C1: Thioglycoside glycosylation (35 min)

The building block solution (0.10 mmol of BB in 1 mL of CH_2Cl_2 per glycosylation) is delivered to the reaction vessel. After the set temperature is reached, the reaction is started by dropwise addition of the NIS/TfOH activator solution (1.0 mL, excess). The glycosylation conditions are building block dependent⁶ and reported for each synthesis. After completion of the reaction, the solution is drained and the resin is washed with CH_2Cl_2 , CH_2Cl_2 :dioxane (1:2, 3 mL for 20 s) and CH_2Cl_2 (two times, each with 2 mL for 25 s). The temperature of the reaction vessel is increased to 25 °C for the next module.

Module C2: Glycosyl phosphate glycosylation (45 min)

The building block solution (0.05 mmol of BB in 1 mL of CH₂Cl₂ per glycosylation) is delivered to the reaction vessel. After the set temperature is reached, the reaction is started by dropwise addition of the TMSOTf solution (1.0 mL, stoichiometric or catalytic). After completion of the reaction, the solution is drained and the resin is washed with CH_2Cl_2 (six times, each one is with 2 mL for 25 s). The temperature of the reaction vessel is increased to 25 °C for the next module.

Module D: Capping (30 min)

The resin is washed with DMF (two times with 2 mL for 25 s) and the temperature of the reaction vessel adjusted to 25 °C. A pyridine solution (2 mL, $10\%_{v/v}$ in DMF) is delivered into the reaction vessel. After 1 min, the reaction solution is drained and the resin is washed with CH_2Cl_2 (three times with 3 mL for 25 s). Capping solution (4 mL) is delivered into the reaction vessel. After 20 min, the reaction solution is drained and the resin is washed with CH_2Cl_2 (three times with 3 mL for 25 s).

*Time required to reach the desired temperature.

Module E1: Fmoc deprotection (9 min)

The resin is washed with DMF (three times with 2 mL for 25 s) and the temperature of the reaction vessel is adjusted to 25 °C. Fmoc deprotection solution (2 mL) is delivered to the reaction vessel and kept under Ar bubbling. After 5 min, the reaction solution is drained and the resin is washed with DMF (three times with 3 mL for 25 s) and CH2Cl² (five times each with 2 mL for 25 s). The temperature of the reaction vessel is decreased to -20 °C for the next module.

Module E2: Lev deprotection (90 min)

The resin is washed with CH₂Cl₂ (three times with 2 mL for 25 s). CH₂Cl₂ (1.3 mL) is delivered to the reaction vessel and the temperature of the reaction vessel is adjusted to 25 °C. Lev deprotection solution (2 mL) is delivered to the reaction vessel, kept under Ar bubbling for 30 min. This procedure is repeated twice. The reaction solution is drained and the resin is washed with DMF (three times with 3 mL for 25 s) and CH2Cl² (five times each with 2 mL for 25 s).

3.4 Post-AGA manipulations

Module F1: On-resin phosphorylation using H-phosphonate 4

4 was prepared according to a previously established procedure.⁷

A solution of **4** (5 equiv. per hydroxyl group) in anhydrous pyridine (4 mL) is evaporated and dried *in vacuo* overnight. The vacuum-dried resin-bound oligosaccharide is places in a 5 mL fritted syringe and washed with anhydrous CH₂Cl₂ (5 x 4 mL) to ensure high swelling of resin. After removal of CH₂Cl₂, a solution of 4 in anhydrous pyridine (1 mL) is added to the resin-bound oligosaccharide, followed by pivaloyl chloride (5 equiv. per hydroxyl group) in anhydrous pyridine (3 mL) and the suspension is gently shaken at room temperature for 5 h. The reaction solution is drained and the resin is washed with CH2Cl² (5 x 4 mL). A solution of iodine (20 equiv. per hydroxyl group) in pyridine/H₂O (4 mL, v/v, 19:1) is added and the mixture is gently shaken at room temperature for another 2 h. The reaction solution is drained and the resin is repeatedly washed with CH_2Cl_2 $(5 x 4 mL)$.

Module F2: On-resin phosphorylation using phosphoramidite 5

5 was prepared according to a previously established procedure.⁸

A solution of **5** (5 equiv. per hydroxyl group) in anhydrous pyridine (4 mL) is evaporated and dried *in vacuo* overnight. The vacuum-dried resin-bound oligosaccharide is places in a 5 mL fritted syringe and washed with anhydrous CH₂Cl₂ (5 x 4 mL) to ensure high swelling of resin. After removal of CH₂Cl₂, a solution of 5 in anhydrous CH₂Cl₂ (2 mL) is added to the resin-bound oligosaccharide, followed by tetrazole, 3 to 4 wt.% solution in MeCN (5 equiv. per hydroxyl group) in anhydrous $CH_2Cl_2(2 \text{ mL})$. The suspension is gently shaken at room temperature for 5 h. The reaction solution is drained and the resin is washed using CH_2Cl_2 (5 x 4 mL). A solution of iodine (20 equiv. per hydroxyl group) in pyridine/H2O (4 mL, v/v, 19:1) is added and the mixture is gently shaken at room temperature for another 2 h. The reaction solution is drained and the resin is repeatedly washed with CH_2Cl_2 (5 x 4 mL).

Module G: On-resin methanolysis

The resin is suspended in THF (4 mL). MeONa in MeOH (0.5 M, 0.4 mL) is added and the suspension is gently shaken at room temperature. After micro-cleavage (see *Module H2*) indicates the complete removal of all ester groups, the reaction solution is drained and the resin is repeatedly washed with MeOH (5 x 4 mL) and CH_2Cl_2 $(5 \times 4 \text{ mL}).$

Module H1: Cleavage from solid support

The oligosaccharide is cleaved from the solid support using a continuous-flow photoreactor as described previously.⁹

Module H2: Micro-cleavage from solid support

Trace amount of resin (around 20 beads) is dispersed in CH₂Cl₂ (0.1 mL) and irradiated with a UV lamp (6 W, 356 nm) for 10 min. MeCN (10 μ L) is then added to the resin and the resulting solution is analyzed by MALDI.

Module I: Hydrogenolysis at ambient pressure

The crude compound obtained from *Module H1* is dissolved in 2 mL of EtOAc:*t*BuOH:H2O (2:1:1). $Pd(OH)_2/C$ (2.5 times the weight of the starting material) is added to the stirred vial, the reaction is purged for 5 min with a N² balloon, and equipped with a H² balloon. The reaction progress is monitored to avoid undesired side products formation (*i.e.* degradation of reducing end).¹⁰ Upon completion, prior to filtration, thiourea (10 equiv.) is added to the reaction. The mixture is filtered (PTFE 0.45 μm 25 mm syringe filter, Fisher scientific) and washed with EtOAc, H2O, and MeCN (4 mL each). The filtrates are concentrated *in vacuo.*

Module J: Purification

The final compounds are analyzed using analytical reversed phase HPLC (Agilent 1200 Series, Methods J3, J5 and J7). The purification of each crude is conducted using manual Sephadex® LH-20 column (Methods J1 and J2) and reverse phase HPLC (Agilent 1200 Series, Methods J4, J6 and J8).

- **Method J1:** Sephadex® LH-20 column with CH₂Cl₂:MeOH (1:1) as eluent, isocratic.
- **Method J2**: Sephadex® LH-20 column with H₂O:MeOH (1:1) as eluent, isocratic.
- Method J3: (Hypercarb column, ThermoFisher scientific, 150 x 4.6 mm, 3 μm) flow rate of 0.7 mL/min with H_2O (0.1% formic acid) and MeCN as eluents [isocratic (5 min), linear gradient to 50% MeCN (30 min), linear gradient to 100% MeCN (5 min), isocratic 100% MeCN (10 min)].
- **Method J4 (Prep)**: (Hypercarb column, ThermoFisher scientific, 150 x 10 mm, 5 μm), flow rate of 3 mL/min with H2O (0.1% formic acid) and MeCN as eluents [isocratic (5 min), linear gradient to 50% MeCN (30 min), linear gradient to 100% MeCN (5 min), isocratic 100% MeCN (10 min)].
- Method J5: (Synergi Hydro RP18 column, Phenomenex, 250 x 4.6 mm), flow rate of 1.0 mL/min with H2O (0.1% formic acid) and MeCN as eluents [isocratic (5 min), linear gradient to 5% MeCN (10 min), linear gradient to 20% MeCN (10 min), isocratic 100% (MeCN 15 min)].
- **Method J6 (Prep)**: (Synergi Hydro RP18 column, Phenomenex, 250 x 10 mm) flow rate of 4.0 mL/min with H2O (0.1% formic acid) and MeCN as eluents [isocratic (5 min), linear gradient to 5% MeCN (10 min), linear gradient to 100% MeCN (5 min), isocratic 100% MeCN (15 min)].
- **Method J7**: (Hypercarb column, ThermoFisher scientific, 150 x 4.6 mm, 3 μm) flow rate of 0.7 mL/min with H2O (0.1% formic acid) and MeCN as eluents [isocratic 20% MeCN (5 min), linear gradient to 50% MeCN (20 min), linear gradient to 100% MeCN (10 min)].
- **Method J8 (Prep)**: (Hypercarb column, ThermoFisher scientific, 150 x 10 mm, 5 μm), flow rate of 3 mL/min with H2O (0.1% formic acid) and MeCN as eluents [isocratic 20% MeCN (5 min), linear gradient to 50% MeCN (20 min), linear gradient to 100% MeCN (10 min)].
- **Method J9**: (Synergi Hydro RP18 column, Phenomenex, 250 x 4.6 mm), flow rate of 1.0 mL/min with H2O (0.1% formic acid) and MeCN as eluents [isocratic (5 min), linear gradient to 5% MeCN (10 min), linear gradient to 30% MeCN (20 min), isocratic 100% (MeCN 5 min)].

3.5 Characterization of phosphorylating reagent 4 and 5

Characterization of 4: 1H NMR (400 MHz, CDCl3) δ 7.28 – 7.22 (m, 5H), 6.17 (br, 1H), 5.96 (br, 1H), 5.00 (s, 2H), 3.90 – 3.85 (m, 2H), 3.36 (dd, *J* = 10.8 Hz, 5.6 Hz, 2H), 2.95 (dd, *J* = 15.6 Hz, 7.6 Hz, 7H), 1.22 (t, *J* = 7.2 Hz, 9H). 31P NMR (162 MHz, CDCl3) δ 5.49.

¹H NMR of 4 (400 MHz, CDCl3)

Characterization of 5: 1H NMR (400 MHz, CDCl3) δ 7.29 – 7.16 (m, 10H), 5.23 (br, 1H), 5.02 (s, 2H), 4.70 – 4.56 (m, 2H), 3.68 – 3.54 (m, 4H), 3.35 (q, *J* = 5.2 Hz, 2H), 1.13 (d, *J* = 6.8 Hz, 12H). 31P NMR (162 MHz, CDCl3) δ 147.85.

4. Oligosaccharide synthesis

Figure S2 Collection of pEtN-cellulose analogues synthesized by AGA.

4.1 Optimization of solid-phase synthesis of pEtN-modified glucoside P

Scheme S1 Synthetic routes for **P**

Table S1 Screening of condition using **4**.

^a Results analyzed after oxidation step.

deprotections.

Table S2 Screening of condition using **5**.

^a Results analyzed after oxidation step.

4.1.1 Mass spectrometry and additional information

Analysis of intermediate 7

Figure S2 MALDI-ToF of compound **7** after microcleavage (positive mode).

Analysis of intermediate 8

Figure S3 MALDI-ToF of compound **8** after microcleavage (positive mode).

Analysis of the intermediate 9

Figure S4 ESI-MS of compound **9** after microcleavage (positive mode).

Analysis of the intermediate 10

Figure S5 ESI-MS of compound **9** after photocleavage (positive mode).

4.2 Synthesis of P

Automated synthesis, global deprotection, and purification afforded **P** as white solid (1.9 mg, 36% overall yield).

¹H NMR (400 MHz, D2O) δ 4.43 (d, *J* = 8.0 Hz, 1H), 4.10 – 3.99 (m, 4H), 3.88 – 3.84 (m, 1H), 3.67 – 3.63 (m, 1H), 3.51 – 3.50 (br, 1H), 3.44 – 3.41 (m, 2H), 3.23 – 3.19 (m, 3H), 2.96 (t, *J* = 7.6 Hz, 2H), 1.66 – 1.58 (m, 4H), 1.44 – 1.37 (m, 2H). ³¹P NMR (162 MHz, D₂O) δ 0.25. ESI-MS m/z 389.1 [M+H]⁺ (C₁₃H₃₀N₂O₉P requires 389.1683). Analytical data of **P** are in good agreement with previously reported data.¹¹

H NMR of P (400 MHz, D2O)

4.3 Synthesis of PAP

PAP

Automated synthesis, global deprotection, and purification afforded **PAP** as white solid (0.7 mg, 7% overall yield).

¹H NMR (600 MHz, D2O) δ 5.18 (d, *J* = 4.2 Hz, 0.4H, H1-α), 4.64. (d, *J* = 7.8 Hz, 0.6H, H1-β), 4.56 (dd, *J*= 7.8 Hz, 2.4 Hz, 1H), 4.49 (d, *J*= 7.8 Hz, 1H), 4.16 – 4.01 (m, 10H), 3.95 – 3.93 (d, *J*= 12.6 Hz, 1H), 3.80 – 3.77 (m, 1H), 3.69 – 3.67 (m, 1H), 3.65 – 3.54 (m, 6H), 3.50 – 3.45 (m, 2H), 3.32 – 3.21 (m, 7H). ³¹P NMR (243 MHz, D₂O) δ 0.34, 0.04, -0.01. HRMS (QToF) m/z 751.1946 [M+H]⁺ (C₂₂H₄₅N₂O₂₂P₂ requires 751.1934).

RP-HPLC of PAP (ELSD trace, Method J3, t^R = 18.1, 18.3 min)

³¹P NMR of PAP (243 MHz, D2O)

5.9 5.8 5.7 5.6 5.5 5.4 5.3 5.2 5.1 5.0 4.9 4.8 4.7 4.6 4.5 4.4 4.3 4.2 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6

4.4 Synthesis of PA⁵

 $PA₅$

Automated synthesis, global deprotection, and purification afforded **PA⁵** as white solid (0.6 mg, 4% overall yield).

¹H NMR (700 MHz, D2O) δ 5.17 (d, *J* = 4.9 Hz, 0.4H, H1-α), 4.61 (d, *J* = 9.1 Hz, 0.6H, H1-β), 4.49 (d, *J*= 9.1 Hz, 5H), 4.02 – 4.01 (m, 1H), 3.94 – 3.89 (m, 3H), 3.83 – 3.75 (m, 5H), 3.64 – 3.51 (m, 16H), 3.49 – 3.44 (m, 1H), 3.32 – 3.27 (m, 4H), 3.13 – 3.20 (m, 1H). ³¹P NMR (243 MHz, D2O) δ 0.29. HRMS (QToF) m/z 1114.346 [M+H]+ (C₃₈H₆₉NO₃₄P requires 1114.343).

³¹P NMR of PA⁵ (162 MHz, D2O)

5.9 5.8 5.7 5.6 5.5 5.4 5.3 5.2 5.1 5.0 4.9 4.8 4.7 4.6 4.5 4.4 4.3 4.2 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6

4.5 Synthesis of A3PA²

Automated synthesis, global deprotection, and purification afforded **A3PA²** as white solid (0.7 mg, 5% overall yield).

¹H NMR (400 MHz, D2O) δ 5.19 (d, *J* = 4.0 Hz, 0.4H, H1-α), 4.63 (d, *J* = 8.4 Hz, 0.6H, H1-β), 4.56 – 4.46 (m, 5H), 4.23 (dd, *J*= 12.4 Hz, 4.4 Hz, 1H) 4.14 – 4.11 (br, 1H), 4.07 (q, *J* = 5.6, 2H), 3.96 – 3.52 (m, 30H), 3.49 – 3.43 (m, 2H), 3.40 – 3.22 (m, 7H), 3.18 (t, *J* = 4.8 Hz, 2H). ³¹P NMR (162 MHz, D2O) δ 0.09. HRMS (QToF) m/z 1114.346 [M+H]⁺ (C₃₈H₆₉NO₃₄P requires 1114.343).

RP-HPLC of A_3PA_2 **(ELSD trace, Method J5,** $t_R = 15.2$ **, 15.5** min)

P NMR of A3PA² (162 MHz, D2O)

4.6 Synthesis of APA⁴

Automated synthesis, global deprotection, and purification afforded **APA⁴** as white solid (2.2 mg, 15% overall yield).

¹H NMR (600 MHz, D2O) δ 5.18 (d, *J* = 3.6 Hz, 0.4H, H1-α), 4.62 (d, *J* = 7.8 Hz, 0.6H, H1-β), 4.52 – 4.48 (m, 5H), 4.22 (dd, *J*= 12 Hz, 4.8 Hz, 1H) 4.12 – 4.10 (m, 1H), 4.04 – 4.01 (m, 2H), 3.94 – 3.86 (m, 5H), 3.83 –3.67 $(m, 8H)$, $3.65 - 3.52$ (m, 11H), $3.49 - 3.44$ (m, 2H), $3.38 - 3.30$ (m, 4H), $3.26 - 3.22$ (m, 2H), 3.14 (t, $J = 4.8$ Hz, 2H), ³¹P NMR (243 MHz, D₂O) δ 0.10. HRMS (QToF) m/z 1114.346 [M+H]⁺ (C₃₈H₆₉NO₃₄P requires 1114.343).

RP-HPLC of APA⁴ (ELSD trace, Method J5, t^R = 15.4, 15.6 min)

P NMR of APA⁴ (243 MHz, D2O)

4.7 Synthesis of A5P

 A_5P

Automated synthesis, global deprotection, and purification afforded **A5P** as white solid (0.6 mg, 4% overall yield).

¹H NMR (700 MHz, D2O) δ 5.18 (d, *J* = 3.5 Hz, 0.4H, H1-α), 4.64 (d, *J* = 7.7 Hz, 0.6H, H1-β), 4.55 – 4.54 (m, 1H), 4.49 (dd, *J*= 16.8 Hz, 7.7 Hz, 4H) 4.15 – 4.04 (m, 5H), 3.94 (d, *J* = 11.2 Hz, 4H), 3.87 (d, *J* = 12.6 Hz, 1H), 3.79 (dd, *J*= 13.3 Hz, 4.9 Hz, 5H), 3.70 – 3.53 (m, 18H), 3.47 – 3.42 (m, 2H), 3.38 (t, *J*= 9.1 Hz, 1H), 3.32 – 3.24 (m, 6H), 3.16 – 3.15 (br, 2H), ³¹P NMR (162 MHz, D2O) δ 0.18, 0.12. HRMS (QToF) m/z 1114.343 [M+H]⁺ (C₃₈H₆₉NO₃₄P requires 1114.343).

RP-HPLC of A5P (ELSD trace, Method J5, t^R = 15.1, 15.2 min)

P NMR of A5P (162 MHz, D2O)

4.8 Synthesis of A2PA³

 A_2PA_3

Automated synthesis, global deprotection, and purification afforded **A2PA³** as white solid (0.4 mg, 3% overall yield).

¹H NMR (600 MHz, D2O) δ 5.19 (d, *J* = 5.4 Hz, 0.4H, H1-α), 4.63 (d, *J* = 12 Hz, 0.6H, H1-β), 4.55 – 4.46 (m, 5H), 4.23 (dd, *J*= 15.6 Hz, 7.8 Hz, 1H), 4.14 – 4.06 (m, 3H), 3.96 – 3.89 (m, 5H), 3.86 – 3.52 (m, 24H), 3.49 – 3.42 (m, 2H), 3.39 – 3.22 (m, 10H), 31P NMR (243 MHz, D2O) δ 0.04. HRMS (QToF) m/z 1114.351 [M+H]⁺ (C38H69NO34P requires 1114.343).

RP-HPLC of A_2PA_3 (ELSD trace, Method J5, $t_R = 14.8$ min)

P NMR of A2PA³ (243 MHz, D2O)

4.9 Synthesis of APA2PA

Automated synthesis, global deprotection, and purification afforded **APA2PA** as white solid (0.4 mg, 2% overall yield).

¹H NMR (700 MHz, D2O) δ 5.18 (d, *J* = 3.6 Hz, 0.4H, H1-α), 4.62 (d, *J* = 6.6 Hz, 0.6H, H1-β), 4.55 – 4.48 (m, 6H), 4.20 – 4.19 (br, 2H), 4.12 – 4.10 (br, 2H), 3.99 – 3.87 (m, 8H), 3.79 – 3.46 (m, 26H), 3.38– 3.23 (m, 8H), 3.06 (s, 3H), ³¹P NMR (162 MHz, D2O) δ 0.25. HRMS (QToF) m/z 1237.351 [M+H]⁺ (C40H75NO37P² requires 1237.351).

RP-HPLC of APA_2PA (ELSD trace, Method J7, $t_R = 15.6$ min)

5.9 5.8 5.7 5.6 5.5 5.4 5.3 5.2 5.1 5.0 4.5 6.4.7 4.6 4.5 4.4 4.3 4.2 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6

4.10 Synthesis of APA3P

Automated synthesis, global deprotection, and purification afforded **APA3P** as white solid (0.9 mg, 6% overall yield).

¹H NMR (400 MHz, D2O) δ 5.21 (d, *J* = 3.6 Hz, 0.4H, H1-α), 4.67 (d, *J* = 7.6 Hz, 0.6H, H1-β),) 4.58 – 4.50 (m, 5H), 4.23 – 4.10 (m, 8H) 3.97 – 3.88 (m, 3H) 3.82 – 3.55 (m, 19H), 3.52 – 3.46 (m, 2H), 3.41 – 3.25 (m, 11H), ³¹P NMR (162 MHz, D₂O) δ 0.01, -0.01, -0.04. HRMS (QToF) m/z 1237.354 [M+H]⁺ (C₄₀H₇₅NO₃₇P₂ requires 1237.351).

RP-HPLC of APA3P (ELSD trace, Method J5, t^R = 13.6, 13.7 min)

4.11 Synthesis of (AP)³

 $(AP)_{3}$

48

Automated synthesis, global deprotection, and purification afforded **(AP)³** as white solid (0.9 mg, 7% overall yield).

¹H NMR (700 MHz, D2O) δ, 5.16 (d, *J* = 3.5 Hz, 0.4H, H1-α), 4.62 (d, *J* = 7.7 Hz, 0.6H, H1-β),) 4.54 – 4.47 (m, 5H), 4.19 – 4.00 (m, 14H) 3.92 (d, *J* = 14 Hz, 2H), 3.86 (d, *J* = 7 Hz, 1H), 3.77 – 3.42 (m, 23H), 3.35 – 3.14 (m, 14H), ³¹P NMR (162 MHz, D₂O) δ 0.08, 0.03. HRMS (QToF) m/z 1360.3546 [M+H]⁺ (C₄₂H₈₁N₃O₄₀P₃ requires 1360.3604).

RP-HPLC of AP)³ (ELSD trace, Method J9, $t_R = 5.8$ min)

5.9 5.8 5.7 5.6 5.5 5.5 4.5 5.7 5.6 5.5 5.4 5.3 5.2 5.1 5.0 4.9 4.8 4.7 4.6 4.5 4.4 4.3 4.2 4.1 4.0 3.9 3.8 3.7 3.6 3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6

5. References

- (1) Eller, S.; Collot, M.; Yin, J.; Hahm, H. S.; Seeberger, P. H. Automated Solid-Phase Synthesis of Chondroitin Sulfate Glycosaminoglycans. *Angew. Chemie - Int. Ed.* **2013**, *52*, 5858–5861. https://doi.org/10.1002/anie.201210132.
- (2) Dallabernardina, P.; Schuhmacher, F.; Seeberger, P. H.; Pfrengle, F. Automated Glycan Assembly of Xyloglucan Oligosaccharides. *Org. Biomol. Chem.* **2016**, *14*, 309–313. https://doi.org/10.1039/C5OB02226F.
- (3) Tyrikos-Ergas, T.; Sletten, E. T.; Huang, J.-Y.; Seeberger, P. H.; Delbianco, M. On Resin Synthesis of Sulfated Oligosaccharides. *Chem. Sci.* **2022**, *13*, 2115–2120. https://doi.org/10.1039/D1SC06063E.
- (4) Le Mai Hoang, K.; Pardo-Vargas, A.; Zhu, Y.; Yu, Y.; Loria, M.; Delbianco, M.; Seeberger, P. H. Traceless Photolabile Linker Expedites the Chemical Synthesis of Complex Oligosaccharides by Automated Glycan Assembly. *J. Am. Chem. Soc.* **2019**, *141*, 9079–9086. https://doi.org/10.1021/jacs.9b03769.
- (5) Gude, M.; Ryf, J.; White, P. D. An Accurate Method for the Quantitation of Fmoc-Derivatized Solid Phase Supports. *Lett. Pept. Sci.* **2002**, *9*, 203–206. https://doi.org/doi.org/10.1023/A:1024148619149.
- (6) Tuck, O. T.; Sletten, E. T.; Danglad‐Flores, J.; Seeberger, P. H. Towards a Systematic Understanding of the Influence of Temperature on Glycosylation Reactions. *Angew. Chemie Int. Ed.* **2022**, *202115433*. https://doi.org/10.1002/anie.202115433.
- (7) Tsai, Y. H.; Götze, S.; Vilotijevic, I.; Grube, M.; Silva, D. V.; Seeberger, P. H. A General and Convergent Synthesis of Diverse Glycosylphosphatidylinositol Glycolipids. *Chem. Sci.* **2013**, *4*, 468– 481. https://doi.org/10.1039/c2sc21515b.
- (8) Campbell, A. S.; Fraser-Reid, B. Support Studies for Installing the Phosphodiester Residues of the Thy-1 Glycoprotein Membrane Anchor. *Bioorganic Med. Chem.* **1994**, *2*, 1209–1219. https://doi.org/10.1016/S0968-0896(00)82072-6.
- (9) Hurevich, M.; Kandasamy, J.; Ponnappa, B. M.; Collot, M.; Kopetzki, D.; McQuade, D. T.; Seeberger, P. H. Continuous Photochemical Cleavage of Linkers for Solid-Phase Synthesis. *Org. Lett.* **2014**, *16*, 1794–1797. https://doi.org/10.1021/ol500530q.
- (10) Ohara, K.; Lin, C.-C.; Yang, P.-J.; Hung, W.-T.; Yang, W.-B.; Cheng, T.-J. R.; Fang, J.-M.; Wong, C.- H. Synthesis and Bioactivity of β-(1→4)-Linked Oligomannoses and Partially Acetylated Derivatives. *J. Org. Chem.* **2013**, *78*, 6390–6411. https://doi.org/10.1021/jo4005266.
- (11) Tyrikos-Ergas, T.; Gim, S.; Huang, J.; Pinzón Martín, S.; Varón Silva, D.; Seeberger, P. H.; Delbianco, M. Synthetic Phosphoethanolamine-Modified Oligosaccharides Reveal the Importance of Glycan Length and Substitution in Biofilm-Inspired Assemblies. *Nat. Commun.* **2022**, *13*, 3954–3961. https://doi.org/10.1038/s41467-022-31633-5.